Nimbus Therapeutics Added Three Senior Leaders
The Boston-based company appointed a new chief business officer along with two other senior executive roles.
Updated on Oct. 13, 2026 in People
Live Poll
Do you trust that new corporate leadership typically improves a company's long-term performance?
Nimbus Therapeutics has expanded its leadership team by appointing Lizabeth Leveille as chief business officer. The company also added Fang Wang as head of biology and promoted Daniel Price to head of chemistry.
Why it matters
These strategic appointments aim to bolster the computational drug discovery firm's internal business development and research capabilities. By scaling its executive team, the company looks to strengthen its focus on advancing its pipeline.
Nimbus Therapeutics announced a total of 3 senior leadership appointments to its core management team. These changes represent a significant expansion of the Boston firm's business development and research departments.
The players
Lizabeth Leveille
She serves as the newly appointed chief business officer at the Boston-based drug discovery firm.
Fang Wang
She is the new senior vice president and head of biology at Nimbus Therapeutics.
Daniel Price
He is the newly promoted senior vice president and head of chemistry at Nimbus Therapeutics.
Nimbus Therapeutics
This Boston-based company utilizes computational methods to accelerate the discovery and development of new drugs.
The details
The firm, which specializes in computational drug discovery, brought on Lizabeth Leveille to oversee business strategy. Additionally, Fang Wang joined as senior vice president and head of biology, while Daniel Price stepped into the role of senior vice president and head of chemistry.
Timeline
Nimbus Therapeutics announced the leadership changes on October 13, 2026.
Market Landscape
This strategic hiring spree reflects the broader trend of executive scaling within the Boston biotech ecosystem. The moves position the firm to remain competitive in a crowded sector where computational drug discovery expertise is in high demand.
These executive changes signal the internal growth of a local company that could result in a more robust drug pipeline. Residents and investors should watch for future updates regarding the specific therapeutic areas these new leaders will prioritize.
The takeaway
Building out a leadership team with specific subject matter expertise is a standard move for firms looking to move research projects toward clinical trials. Staying informed on key executive moves helps observers track which specific research sectors a company intends to prioritize.
Further reading
For more on industry hiring, visit our Boston People section.
Live Poll
Do you trust that new corporate leadership typically improves a company's long-term performance?
